WHO announces 4 promising new coronary pneumonia treatments: large-scale clinical trials to be launched

The World Health Organization (WHO) is working with its partners to develop at least 20 potential new coronavirus vaccines, the only treatment that could eradicate the new coronavirus,media reported. Although at least two clinical trials are under way, the treatment will take 12 to 18 months. At the same time, WHO is working separately to improve treatment for new coronary pneumonia.


The purpose of this extensive test is to allow doctors to use existing resources to provide the best treatment for patients. Drugs previously approved for treating other diseases could be used to improve the condition of hundreds of thousands of patients admitted to hospitals around the world with new coronary pneumonia, speed up recovery and reduce deaths. By contrast, it could take years to develop a new drug specifically for the new coronary pneumonia disease.

The study, called Solidarity, is designed to determine which of the four most popular treatmentoptions is the most effective and safest for patients.

The trial will include thousands of patients from several countries including Argentina, Bahrain, Canada, France, Iran, Norway, South Africa, Spain, Switzerland and Thailand. ScienceMag also reported that France’s National Institute of Medicine (INSERM) is coordinating an additional trial in Europe called Discovery, which will include 3,200 patients from seven countries, including the Three Kingdoms of Germany, France, Spain and the United Kingdom.

In addition to chloroquine, other drugs being tested in Solidarity and Discovery will be similar, although chloroquine will not be used in European-only trials.

Unlike conventional double-blind clinical trials, the new study will test new treatments in all patients. A routine clinical trial is a double-blind clinical trial so that patients don’t know if they’re taking a tested drug or a placebo. Doctors will enter patient data on the WHO website, including existing conditions that may change the course of the disease, and participants must sign an informed consent form. Doctors will also list the drugs available in hospitals, and WHO will randomly assign patients to use a available treatment. After that, the doctor only needs to record the date of the patient’s discharge or death and whether he or she needs oxygen absorption or ventilation.

WHO announces 4 promising new coronary pneumonia treatments: large-scale clinical trials to be launched

WHO announces 4 promising new coronary pneumonia treatments: large-scale clinical trials to be launched

The drug ridsieve, used to fight the Ebola virus, appears to be the most promising of the four therapies, as the experimental drug has been shown to be effective against both SARS and MERS viruses.

The two drugs, chloroquine and hydroxychloroquine, are on who’ consolidated list. French researchers also say the drugs are expected to treat the new coronavirus, but the results need to be more widely tested. Some scientists worry that the dose required to fight the new coronavirus may be too high to be considered. There have been reports of cases of chloroquine poisoning in Nigeria.

In addition, Solidarity will test an antiviral drug called Kaletra’s Litonavir/Lobinavir, which is also used in AIDS treatment. Although the combination of therapies had little effect in China, the study included only severe subjects, with more than one-half of the 199 patients who had been tested for double-blindness having died. Perhaps it’s because the drug was prescribed too late to do anything.

The fourth treatment, which will be tested in countries involved in the Solidarity and Discovery projects, will mix Litonavir/Lobinawe with interferon. This combination has been used in the treatment of patients with MERS in Saudi Arabia. But if treatment is too late, it can cause unnecessary side effects, and according to Herold, it can cause more serious tissue damage and does not help patients.